About Nasal Polyps Treatment
Nasal polyps are fleshy swelling that develops in the lining of the nose and paranasal sinuses, the air-filled spaces that are linked to the nasal cavity. It varies in size and may be yellowish-brown or pink. It shaped like teardrops. Large nasal polyps or clusters can cause breathing difficulties and may affect the patient’s sense of smell. It may block sinuses and cause problems. It cannot be cured but they can be treated with medications. Corticosteroid nasal sprays and pills are the most frequently used medications for treating nasal polyps. The antibiotics can be prescribed if the patient has a sinus infection caused by bacteria.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Nasal Polyps Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
OptiNose US, Inc. (United States), Regeneron Pharmaceuticals, Inc. (United States), Merck KGaA (Germany), Pfizer, Inc. (United States), Roche Holding AG (Switzerland), Intersect ENT, Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Novartis (United States), Sanofi (France) and Taro Pharmaceutical Industries Ltd. (United States) are some of the key players that are part of study coverage.
Segmentation Overview
AMA Research has segmented the market of Global Nasal Polyps Treatment market by , Application (Hospitals, Clinics, Research Center and Other) and Region.
On the basis of geography, the market of Nasal Polyps Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medications will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. CT Scan will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Runny Nose will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Technological advancements in the treatment
Market Growth Drivers:
Increase in the prevalence of ENT diseases and Rising regulatory approvals for nasal polyp treatment
Challenges:
No complete cure of nasal polyps available
Restraints:
Side effects of the treatment of nasal polyps
Opportunities:
Rising number of hospitals and diagnostic centers worldwide and Development of Healthcare Infrastructure in Emerging Economies
Market Leaders and their expansionary development strategies
In January 2024, GSK and Aiolos Bio, a clinical-stage biopharmaceutical company specializing in the treatment of respiratory and inflammatory conditions, announced that they have entered into an agreement for GSK to acquire Aiolos. hrough the acquisition, GSK will gain access to Aiolos’ AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) that is ready to enter Phase II clinical development. The mAb is being evaluated for the treatment of adult patients with asthma.
On 26th June 2019, The United States Food and Drug Administration approved Dupixent (Dupilumab) to treat adults with nasal polyps accompanied by chronic rhinosinusitis. This is the first treatment approved for inadequately controlled chronic rhinosinusitis with nasal polyps. and In July 2021,,GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This new indication for mepolizumab is for the add-on maintenance treatment of CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.
Key Target Audience
Nasal Polyps Treatment Providers, Research Professionals, Emerging Companies, Government Body & Associations and End-user
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.